Yoshihiro Kawaoka, DVM, Ph.D., Founder and Chief Scientific Affairs Consultant
Dr. Kawaoka has been studying influenza viruses for more than 20 years. His work has helped to answer key questions in influenza virus research such as how influenza viruses cause disease, why certain types of influenza viruses are found in humans while other types are found only in birds and how influenza viruses change over time. In 2006, Dr. Kawaoka was awarded the prestigious Robert Koch Award for his innovative research in the field of influenza virology.
Dr. Kawaoka’s work has proven to be practical as well as innovative. Most notably he and his team established a system for the generation and manipulation of influenza viruses known as “reverse genetics”- a development which has revolutionized the field of influenza research. Scientists are now able to modify the virus at will in order to address specific questions and to develop new and improved vaccines.
Dr. Kawaoka currently maintains joint appointments and highly active influenza research programs at both the University of Wisconsin-Madison and the University of Tokyo. Recently, his research interest has shifted to the development of improved influenza virus vaccines and anti-virals.
Gabriele Neumann, Ph.D., Founder and Scientific Affairs and Grants Consultant
Dr. Neumann brings both significant academic and industry experiences to FluGen Inc. She is a trained molecular virologist with more than 15 years working with the influenza virus. During her graduate studies in Germany, she developed a system that allows the artificial generation of pieces of influenza virus. This work was instrumental in the breakthrough of “reverse genetics” during her postdoctoral fellowship in Dr. Kawaoka’s research group. Dr. Neumann used this system for the artificial generation of live influenza viruses and for this accomplishment she was awarded the Loeffler-Frosch Award in 2000.
Dr. Neumann continues to study the influenza virus life cycle and to devise improved systems for the generation of vaccine viruses. The ability to manipulate influenza viruses builds the foundation for the development of new or improved influenza virus vaccines and antivirals, as proposed by FluGen, Inc. In 2000, Dr. Neumann took her detailed knowledge of and experience with influenza virus research to Wyeth where as a Senior Scientist she worked on the development of FluMistTM/ CAIV-T. In 2002, she rejoined Dr. Kawaoka’s research group, where she currently holds the position of Research Associate Professor.
John Treanor, M.D.
Dr. Treanor is an infectious disease specialist in Rochester, New York. He received his medical degree from University of Rochester School of Medicine and Dentistry and has been in practice for more than 20 years. He is the Director of the New York Influenza Center of Excellence and is a former voting member of the Advisory Committee on Immunization Practices (ACIP). Dr. Treanor serves on editorial boards and is a reviewer for multiple publications in the field of infectious diseases. He has been involved in a number of clinical studies for virtually all marketed and some novel influenza vaccines.
Harry Greenberg, M.D.
Dr. Greenberg is currently the Senior Associate Dean for Research at Stanford University School of Medicine and the Director of Spectrum, the Stanford NIH funded CTSA. He is also the Joseph D. Grant Professor of Medicine and Microbiology and Immunology at Stanford Medical School. He is an author of over 400 publications and is the recipient of many honorary awards. Most recently Dr. Greenberg was recognized as the Recipient of the Gold Medal Award from Columbia College of Physicians and Surgeons for Distinguished Achievements on Research.
Robert B. Belshe, MD
Dr. Belshe is the Diana and J. Joseph Adorjan Endowed Professor of Infectious Diseases and Immunology at Saint Louis University. He is an expert in clinical trials design and execution, and his laboratory focuses on antibody responses to viral vaccines, including influenza, RSV and vaccinia. He chaired the NIH/industry cooperative Phase 3 pivotal licensing studies on live attenuated influenza vaccine, he conducted the vaccinia dilution studies for the NIH biodefense initiative and most recently he chaired the NIH and GSK Herpevac Trial for Women.